Abstract
Bioreactors are widely used in cell culture-based viral vaccine production, especially during the coronavirus disease 2019 (COVID-19) pandemic. In this context, the development and application of bioreactors can provide more efficient and cost-effective vaccine production to meet the global vaccine demand. The production of viral vaccines is inseparable from the development of upstream biological processes. In particular, exploration at the laboratory-scale is urgently required for further development. Therefore, it is necessary to evaluate the existing upstream biological processes, to enable the selection of pilot-scale conditions for academic and industrial scientists to maximize the yield and quality of vaccine development and production. Reviewing methods for optimizing the upstream process of virus vaccine production, this review discusses the bioreactor concepts, significant parameters and operational strategies related to large-scale amplification of virus. On this basis, a comprehensive analysis and evaluation of the various process optimization methods for the production of various viruses (SARS-CoV-2, Influenza virus, Tropical virus, Enterovirus, Rabies virus) in bioreactors is presented. Meanwhile, the types of viral vaccines are briefly introduced, and the established animal cell lines for vaccine production are described. In addition, it is emphasized that the co-development of bioreactor and computational biology is urgently needed to meet the challenges posed by the differences in upstream production scales between the laboratory and industry.
Introduction
The COVID-19 pandemic underscored a critical global challenge: the need to produce billions of vaccine doses rapidly and cost-effectively. Traditional vaccine production methods, such as utilizing chicken eggs for influenza vaccines, are inherently slow, labor-intensive, and difficult to scale. Cell culture-based production in bioreactors offers a superior alternative, yet the transition from laboratory flasks to 10,000-liter industrial tanks involves significant engineering hurdles. This review addresses the "upstream" challenges of maintaining high-density cell populations as productive viral factories while managing physical constraints like shear stress, oxygen limitations, and metabolic waste.
Bioreactor Architectures and Operational Strategies
Successful vaccine manufacturing relies on selecting the appropriate bioreactor architecture and operational mode. Common systems include mechanical stirring, airlift, hollow fiber, and fixed-bed reactors (e.g., iCELLis®).
A major shift in the industry is the move from simple batch and fed-batch cultures toward perfusion systems. Perfusion utilizes technologies like Alternating Tangential Flow (ATF) to continuously supply fresh nutrients and remove waste while retaining cells within the reactor. This allows for significantly higher cell densities and a "steady state" environment that prevents the accumulation of toxic byproducts like lactic acid.
Optimization and Computational Modeling
Maximizing yield requires the precise fine-tuning of physical and chemical variables, including pH, dissolved oxygen (DO), temperature, and the Multiplicity of Infection (MOI). However, physical gradients found in massive reactors often differ from laboratory beakers. To bridge this gap, the integration of computational biology—specifically Computational Fluid Dynamics (CFD) and Agent-Based Modeling (ABM)—is essential. These "digital twins" allow researchers to simulate the bioreactor environment and identify "dead zones" before physical scaling begins.
Key Results across Viral Platforms
Meta-analysis of recent experimental data demonstrates the efficacy of optimized bioreactor processes across various pathogens:
- SARS-CoV-2: Fixed-bed reactors (CelCradle™) have achieved titers of 7.3 log10 TCID50/mL, outperforming traditional monolayer cultures.
- Influenza (H1N1): Semi-perfusion environments using MDCK cells have reached infectious titers of 1.83 × 10¹⁰ virions/mL.
- Tropical Viruses: Zika virus production in EB66® cells using perfusion systems reached 1.0 × 10¹⁰ PFU/ml.
- Other Pathogens: Significant yield improvements have been documented for Enterovirus 71, Rabies, and Ebola virus using specialized cell lines like Vero, HEK293, and AGE1.CR.pIX.
Discussion and Future Prospects
Despite these advancements, several limitations remain. The "cell density effect" suggests that higher cell counts do not always translate to higher specific productivity; finding the intersection of density and individual cell health is critical. Furthermore, enveloped viruses like SARS-CoV-2 are physically fragile and sensitive to the shear stress of large-scale mixing.
Future research must focus on the "translation gap" between lab and industry, ensuring genetic stability during continuous culture and integrating upstream gains with downstream purification processes. The co-development of bioreactor technology and computational modeling remains the most promising path toward meeting global vaccine demands.
Summary updated